Provided by Tiger Trade Technology Pte. Ltd.

Invesco Dorsey Wright Healthcare Momentum ETF

60.83
-0.5341-0.87%
Volume:659
Turnover:40.22K
Market Cap:268.87M
PE:19.90
High:61.34
Open:61.15
Low:60.83
Close:61.36
52wk High:64.10
52wk Low:39.36
Shares:4.42M
Float Shares:4.42M
Volume Ratio:0.21
T/O Rate:0.01%
Dividend:1.53
Dividend Rate:2.51%
EPS(TTM):3.06
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Shandong Oriental Ocean Secures Regulatory Approval for Its Scavenger Receptor-A Assay Kit

Stock News
·
Sep 01

Affordable Housing Stocks Investors Are Watching As Social Spending Moves Center Stage

Simply Wall St.
·
Sep 01

NASD Most Active Issues

Dow Jones
·
Sep 01

Axsome pullback brings attractive entry point, says H.C. Wainwright

TIPRANKS
·
Aug 31

Axsome Therapeutics, - Doses First Patient in Summit Phase 3 Trial of Axs-05 for Smoking Cessation

THOMSON REUTERS
·
Aug 31

Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation

GlobeNewswire
·
Aug 31

Revolution Medicines, Inc. : Needham Raises Target Price to $275 from $240

THOMSON REUTERS
·
Aug 31

Guangdong Hybribio Biotech's Subsidiary Secures In Vitro Diagnostic Device Registration Certificate

Stock News
·
Aug 31

Does Guardant Health’s (GH) Patent Appeal Reshape Its Competitive Moat More Than Its Royalty Bill?

Simply Wall St.
·
Aug 30

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Spyre Therapeutics (SYRE)

TIPRANKS
·
Aug 29

Pharma Industry Stares Down Biggest Patent Cliff in Decades

Dow Jones
·
Aug 29

Immunovant Director Atul Pande Disposes of 1,500 Common Shares Worth $64,905

Reuters
·
Aug 29

Revolution Medicines Set to Post 'Strong Launch' for Rasonque, UBS Says

MT Newswires Live
·
Aug 29

Roivant Sets Price for New Rare Disease Drug Lisraya at $35,000 a Month

Reuters
·
Aug 28

Lisraya is Commercially Available NOW - Roivant Presentation

THOMSON REUTERS
·
Aug 28

Roivant Sciences Exec Says Lisraya Will be Available at List Price of $35,000 for a 30-Day Supply

THOMSON REUTERS
·
Aug 28

Roivant Sciences Price Target Maintained with a $41.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 28

US Regulator Approves Novel Pancreatic Cancer Therapy, Marking Major Win for Independent Biotech

Deep News
·
Aug 28

Why the Drugmaker Behind a Pancreatic Cancer Breakthrough Stayed Independent

Dow Jones
·
Aug 28

Roivant Sciences Gets FDA Approval for LISRAYA in Dermatomyositis; Shares Rise

MT Newswires Live
·
Aug 28